May 18 2021 - Biopharma execs address the challenges of a post-pandemic workplace
Flag link:
Biopharma Execs Address the Challenges of a Post-Pandemic Workplace
Biopharma Execs Address the Challenges of a Post-Pandemic Workplace
BioSpace
pandemic
COVID-19
remote work
Flag link:
Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say
Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say
Fierce Pharma
ICER
drug pricing
corporate citizenship
Flag link:
Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
Endpoints
Sarepta
Duchenne Muscular Dystrophy
clinical trials
gene therapy
Flag link:
Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset
Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset
Fierce Biotech
Bristol Myers Squibb
Agenus
AGEN1777
M&A
Flag link:
Medicago, GSK’s plant-made COVID jab clears phase 2
Medicago, GSK’s plant-made COVID jab clears phase 2
Pharmaforum
GSK
Medicago
vaccines
COVID-19
Canada
clinical trials
Flag link:
Novartis' Sandoz embarks on €150M antibiotics manufacturing upgrade in Europe
Novartis' Sandoz embarks on €150M antibiotics manufacturing upgrade in Europe
Fierce Pharma
Novartis
Sandoz
generics
Europe
drug manufacturing
Flag link:
Novo Nordisk continues pushing beyond diabetes, netting PhII win for former Corvidia kidney program
Novo Nordisk continues pushing beyond diabetes, netting PhII win for former Corvidia kidney program
Endpoints
Novo Nordisk
chronic kidney disease
clinical trials
ziltivekimab
Flag link:
J&J aims to create community for PAH patients and their doctors with new Uptravi campaign
J&J aims to create community for PAH patients and their doctors with new Uptravi campaign
Fierce Pharma
JNJ
PAH
Uptravi
pharma marketing
Flag link:
CMS’ rule granting speedy coverage to FDA-designated ‘breakthrough’ devices delayed again
CMS’ rule granting speedy coverage to FDA-designated ‘breakthrough’ devices delayed again
MedCity News
CMS
Medicare
devices
breakthrough device
FDA
Flag link:
An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up
An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up
Endpoints
OrbiMed
corticosteroids
SPI-62
startups
Sparrow Pharmaceuticals
Flag link:
Bristol’s buy moves it to the top of the sales charts
Bristol’s buy moves it to the top of the sales charts
EP Vantage
Celgene
Bristol-Myers Squibb
M&A
sales reps
Flag link:
Regeneron resumes enrollment in lymphoma drug trials
Regeneron resumes enrollment in lymphoma drug trials
Reuters
Regeneron
clinical trials
FDA
lymphoma
odronextamab
Flag link:
Sales Manager - Pharmaceutical & Diagnostics
Flag link:
Regional Sales Manager – DIAGNOSTICS & PHARMACEUTICALS
Flag link:
Regional Sales Manager – DIAGNOSTICS & PHARMACEUTICALS
Flag link:
Regional Sales Manager – DIAGNOSTICS & PHARMACEUTICALS
Flag link:
Sales Manager - Pharmaceutical & Diagnostics
Flag link:
Sales Manager - Pharmaceutical & Diagnostics
Flag link:
Sales Manager - Pharmaceutical & Diagnostics
Flag link:

Pages